Endocrine factors in the treatment of prostatic cancer.
Pierrepoint
C G
CG
Turkes
A O
AO
Walker
K J
KJ
Harper
M E
ME
Wilson
D W
DW
Peeling
W B
WB
Griffiths
K
K
D002064:Buserelin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002369:Castration; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D003366:Cosyntropin / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004054:Diethylstilbestrol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D017273:Goserelin; D006728:Hormones / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007986:Luteinizing Hormone / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
D006063:Chorionic Gonadotropin; D004967:Estrogens; D006728:Hormones; D017273:Goserelin; D003366:Cosyntropin; D013739:Testosterone; C006418:adrenocorticotropin zinc; D004054:Diethylstilbestrol; D003907:Dexamethasone; D007986:Luteinizing Hormone; C004955:fosfestrol; D002064:Buserelin